Skip to main content

Table 5 Modification of the sweat test and the NPD results after gentamicin treatment.

From: In vitroprediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study

  Group A
n = 9
Group B
n = 4
Group C
n = 5
Patients D0 D15 p D0 D15 p D0 D15 p
Sweat chloride (mM/L) 109(17) 85(31) 0.03 110(7) 112(16) NS 96(1.5) 105(18) NS
Basal PD -56(10) -49(5) 0.12 -53(11) -50(8) NS -52(8) -52(7) NS
ΔAmiloride 20(6) 15(7) 0.09 22(15) 20(9) NS 19(12) 21(13) NS
ΔCl-free-isoproterenol -0.8(1.3) -4.6(6) 0.04 -0.2(0.5) -0.9(1) NS 0(0.5) -0.8(1) NS
  1. Group A: patients with the Y122X stop mutation. Group B: patients with another stop mutation. Group C: patients without any stop mutation. Data are described as mean (SD). Comparison with Wilcoxon test.